• Final NICE yes for Amicus’ Fabry disease drug pharmatimes
    February 23, 2017
    Cost regulators for NHS therapies in England and Wales have now published final guidelines endorsing the use of Amicus Therapeutics' Galafold for treating the rare genetic disorder Fabry disease.
PharmaSources Customer Service